Agnc Investment Corp
Change company Symbol lookup
Select an option...
AGNC Agnc Investment Corp
BYND Beyond Meat Inc
NDENF Central African Gold Inc
HD Home Depot Inc
ACPS AC Partners Inc
FONR Fonar Corp
WBRRFX BlackRock Russell 2000 Growth Index Fund
WSM Williams-Sonoma Inc
BLK BlackRock Inc
TSEM Tower Semiconductor Ltd

Company profile

AGNC Investment Corp., formerly American Capital Agency Corp., is a real estate investment trust. The Company invests in agency residential mortgage-backed securities on a leveraged basis. Its investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by a government-sponsored enterprise, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac), or by the United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) (collectively, GSEs). Its agency securities include agency residential mortgage-backed securities (Agency RMBS) and to-be-announced forward contracts (TBAs). Its Non-Agency Securities include credit risk transfer securities (CRT), non-agency residential mortgage-backed securities (Non-Agency RMBS) and commercial mortgage-backed securities (CMBS).

Closing Price
Day's Change
-0.08 (-0.57%)
B/A Size
Day's High
Day's Low

10-day average volume:

Global Rubella Diagnostic Testing Market Analysis 2020-2025 - Led by Abbott Labs, Bio Rad Labs, bioMerieux, Siemens and Thermo Fisher Scientific -

8:12 am ET August 27, 2020 (BusinessWire) Print

The "Rubella Diagnostic Testing Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to's offering.

The major factors for the growth of the rubella diagnostic testing market include the government initiatives to curb the rubella virus, increasing incidences of rubella, and the introduction of advanced point-of-care diagnostic technologies, which are expected to boost the overall growth of the market over the forecast period.

There has been an increase in the number of incidences of rubella across the world. On the other hand, as per the Global Vaccine Action Plan (GVAP) Assessment report, rubella control is lagging, with 42 countries yet to introduced the vaccine.

Key Market Trends

Enzyme Immunoassay Testing Technique Accounted for the Largest Share

The detection of rubella-specific immunoglobulin M (IgM) in serum is the standard test for the rapid laboratory diagnosis of rubella. IgM testing is the most commonly performed testing technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies that are made by the immune system to kill the rubella virus, and these antibodies remain in the bloodstream for years. The segment is expected to account for the largest market share, owing to the rising incidences of rubella.

Asia-Pacific Accounted for the Highest Growth Rate

The Asia-Pacific segment, by geography, was found to register the fastest growth rate for the rubella diagnostic testing market, and is expected to show a similar trend over the forecast period, without significant fluctuations.

The Asia-Pacific region holds the highest market share, owing to the presence of larger untapped opportunities, a lack of awareness in some countries, and government initiatives to curb the disease incidence.

As per the Global Vaccine Action Plan (GVAP) Assessment report 2017, 42 countries have not yet introduced the vaccine, and two regions, Africa and the Eastern Mediterranean, have not yet set rubella elimination or control targets. Such regions are expected to face high incidences of rubella, which may further drive the growth of the market.

Competitive Landscape

The market studied is dominated by a few major players and most of the players present in the market are focusing on the development of new technologies to acquire the maximum market share. The presence of major market players, such as Abbott Laboratories, Bio Rad Laboratories Inc., bioMerieux SA, Siemens AG, and Thermo Fisher Scientific Inc., is increasing the overall competitive rivalry in the market.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Government Initiatives to Curb Rubella Virus

4.2.2 Increasing Incidences of Rubella

4.2.3 Introduction of Advance Point-of-care Diagnostic Technologies

4.3 Market Restraints

4.3.1 Lack of Awareness among Developing Regions

4.4 Porter's Five Forces Analysis


5.1 Testing Technique

5.1.1 Latex Agglutination

5.1.2 Enzyme Immunoassay (EIA)

5.1.3 Radioimmunoassay (RIA)

5.1.4 Fluorescent Immunoassay (FIA)

5.1.5 Other Testing Techniques

5.2 Application

5.2.1 Hospitals

5.2.2 Laboratories

5.2.3 Other Applications

5.3 Geography

5.3.1 North America

5.3.2 Europe

5.3.3 Asia-Pacific

5.3.4 Middle East & Africa

5.3.5 South America


6.1 Company Profiles

6.1.1 Abbott

6.1.2 Beckman Coulter Inc.

6.1.3 Bio Rad Laboratories Inc.

6.1.4 Biokit SA

6.1.5 bioMerieux SA

6.1.6 F. Hoffmann-La Roche Ltd.

6.1.7 Ortho Clinical Diagnostics

6.1.8 Siemens Healthcare GmbH

6.1.9 Thermo Fisher Scientific

6.1.10 ZEUS Scientific Inc.


For more information about this report visit

View source version on

SOURCE: Research and Markets
Laura Wood, Senior Press Manager 
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.